Combinatorial Regulation of Endothelial Gene Expression by Ets and Forkhead Transcription Factors

Sarah De Val,¹ Neil C. Chi,^{1,2} Stryder M. Meadows,³ Simon Minovitsky,⁴ Joshua P. Anderson,¹ Ian S. Harris,¹ Melissa L. Ehlers,¹ Pooja Agarwal,¹ Axel Visel,⁴ Shan-Mei Xu,¹ Len A. Pennacchio,⁴ Inna Dubchak,⁴ Paul A. Krieg,³ Didier Y.R. Stainier,^{1,2} and Brian L. Black^{1,2,*}

¹Cardiovascular Research Institute

²Department of Biochemistry and Biophysics

University of California, San Francisco, San Francisco, CA 94158-2517, USA

³Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA

⁴Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

*Correspondence: brian.black@ucsf.edu

DOI 10.1016/j.cell.2008.10.049

SUMMARY

Vascular development begins when mesodermal cells differentiate into endothelial cells, which then form primitive vessels. It has been hypothesized that endothelial-specific gene expression may be regulated combinatorially, but the transcriptional mechanisms governing specificity in vascular gene expression remain incompletely understood. Here, we identify a 44 bp transcriptional enhancer that is sufficient to direct expression specifically and exclusively to the developing vascular endothelium. This enhancer is regulated by a composite cis-acting element, the FOX:ETS motif, which is bound and synergistically activated by Forkhead and Ets transcription factors. We demonstrate that coexpression of the Forkhead protein FoxC2 and the Ets protein Etv2 induces ectopic expression of vascular genes in Xenopus embryos, and that combinatorial knockdown of the orthologous genes in zebrafish embryos disrupts vascular development. Finally, we show that FOX:ETS motifs are present in many known endothelial-specific enhancers and that this motif is an efficient predictor of endothelial enhancers in the human genome.

INTRODUCTION

The establishment of the vascular system begins prior to the beating of the heart and initially forms through a process referred to as vasculogenesis. Mesodermal cells differentiate into endothelial cell precursors and form primitive vessels, which are then rapidly remodeled through endothelial sprouting, branching, and intussusception from existing blood vessels (Flamme et al., 1997; Patan, 2004). This highly organized developmental program requires the correct spatial and temporal expression of a large number of genes; yet despite the importance of the vasculature in development and disease, the transcriptional mechanisms governing gene expression in these processes remain incompletely understood.

The Ets family of winged helix proteins plays a clear role in the transcriptional control of genes involved in vascular development (Dejana et al., 2007; Sato, 2001). All Ets factors share a highly conserved DNA-binding domain and bind to the core DNA sequence GGA(A/T), and nearly every endothelial cell enhancer or promoter characterized to date contains multiple essential Ets-binding sites (Dejana et al., 2007; Sato, 2001). Of the nearly 30 different members of the mammalian Ets family, at least 19 are expressed in endothelial cells, and several have been shown to play essential roles in vascular development (Hollenhorst et al., 2004). However, no Ets factor is unique to the vasculature, and Ets-binding sites are not specific to endothelialexpressed genes (Hollenhorst et al., 2004; Maroulakou and Bowe, 2000). Thus, it is unclear exactly how Ets factors contribute to the specificity of endothelial gene regulation. It has been hypothesized that Ets proteins may achieve tissue-specific activation through binding to lower affinity sites in cooperation with other proteins (Hollenhorst et al., 2007), but Ets partners in endothelial cells have yet to be identified.

Members of the Forkhead (Fox) transcription factor family also play important roles in vascular endothelial development. Forkhead transcription factors are helix-turn-helix proteins that typically bind asymmetric *cis*-acting elements of 15–17 bp, containing the core Fox protein consensus of RYMAAYA (Carlsson and Mahlapuu, 2002). FoxC1 and FoxC2 are expressed in the developing vasculature, although not exclusively, and Foxc1/Foxc2 compound null embryos die during embryonic development with profound vascular defects (Hosaka et al., 2004; Seo et al., 2006). However, the mechanisms by which Forkhead transcription factors control endothelial gene expression are not clear. It has been hypothesized that gene expression in the endothelium may be regulated via the combined action of multiple transcription factors, but direct evidence for such a putative combinatorial control mechanism has been lacking.

In the present study, we identified a 44 bp transcriptional enhancer that is sufficient to direct expression specifically and





Figure 1. Identification of a 44 bp Mef2c Endothelial-Specific Enhancer

(A) A schematic representation of the mouse *Mef2c* locus is shown on the top line with exons depicted as vertical lines. The red boxes denote the sizes and positions of the F7 and F10 fragments. F10 contains three evolutionarily conserved regions, denoted CR1–3. The lower portion of (A) depicts the deletion constructs of *Mef2c* F10. CR3 contains a neural crest-specific enhancer. CR2 contains an endothelial-specific enhancer, which encompasses a 44 bp deeply conserved region that is sufficient for endothelial enhancer activity in vivo. Endothelial and neural crest activity of each of the deletion constructs is denoted at the right as a + or -. The total number of transgenic embryos and the number that directed β -galactosidase expression to either the neural crest or endothelium are denoted at the far right of (A).

(B–G) Representative X-gal stained transgenic embryos for each of the Mef2c F10 transgene deletion constructs depicted in (A).

(H–M) Expression of the *Mef2c* F10-44-*lacZ* construct is specific to endothelial cells from blood island (bl) stage at E7.5 (H) throughout early endothelial development at E8.0 (I) and E8.5 (J and K). Transverse sections through an X-gal stained E9.5 transgenic embryo (L and M) demonstrate that transgene expression is restricted to endothelial cells throughout the vasculature, including the endocardium (end). al, allantois; BAA, branchial arch artery; CV, cardinal vein; DA, dorsal aorta; DRG, dorsal root ganglia; ec, ectoplacental cone; hrt, heart; LV, left ventricle; NC, neural crest; NT, neural tube; RV, right ventricle; SV, sinus venosus; YS, yolk sac.

exclusively to the developing vascular endothelium. This enhancer is regulated by a composite *cis*-acting element, the FOX: ETS motif, which is bound and synergistically activated by Forkhead and Ets transcription factors. We demonstrate that coexpression of FoxC2 and the Ets protein Etv2 (Etsrp71, ER71) is sufficient to induce ectopic expression of vascular genes in *Xenopus* embryos, and that combinatorial knockdown of the orthologous genes in zebrafish embryos disrupts vascular development. Finally, we show that FOX:ETS motifs are present in many known endothelial-specific enhancers and that this motif is an efficient predictor of endothelial enhancers in the human genome. Thus, these studies provide insight into the specificity requirements for endothelial gene expression by the combinatorial activities of two widely expressed transcription factors on a single composite *cis*-acting element.

RESULTS

Identification of a 44 bp Enhancer Sufficient to Direct Expression Exclusively to Endothelial Cells in the Developing Embryo

The MEF2C transcription factor is expressed in endothelial cells soon after their initial specification and is essential for vascular development in mice (Lin et al., 1998; Figure S1 available online). Based on evolutionary conservation, we identified a 5.6 kb region of the *Mef2c* locus (F10) that contained two separate enhancers that each direct expression to a single lineage in the developing mouse embryo (Figure 1A). The activity of one enhancer was specific to the developing vascular endothelium (F10E), and the activity of the other was restricted to the neural crest and its derivatives (F10N) at E9.5 (Figures 1A–1D). *Mef2c*

F10E is a distinct regulatory element from a previously identified enhancer, termed Mef2c F7 (Figure 1A), which also directs vascular expression in vivo, although not as early in endothelial development as F10E (De Val et al., 2004). Mef2c F10E contains a highly conserved 44 bp region that shares 86% sequence homology with zebrafish (Danio rerio) (Figure 2A). Deletion of this deeply conserved 44 bp fragment in the context of F10E or in the context of the larger 5.6 kb F10 construct resulted in the complete loss of endothelial expression (Figures 1F and 1G). Remarkably, the 44 bp deeply conserved region of F10 (F10-44) was sufficient to direct endothelial cell-specific expression from the blood island stage at E7.5 through angiogenesis and remodeling at E9.5 (Figures 1E and 1H–1M). These results indicate that this minimal 44 bp region contains all the cis-regulatory information necessary for endothelial-specific gene activation and expression and thus presented the opportunity to identify a minimal set of transcription factors sufficient to regulate endothelial-specific gene expression.

The *Mef2c* F10E Enhancer Is Bound and Synergistically Activated by Fox and Ets Transcription Factors through a Novel *cis*-Acting Motif

To locate transcription factor-binding sites within F10-44, we used DNasel footprinting to identify a region at the 3' end of F10-44 bound by an activity present in endothelial cell extracts but not in extracts from myoblasts (Figure S2). Within this region, we identified a consensus ETS site, containing the core GGA(A/T) motif, referred to as ETS-A (Figure 2A). While multiple Ets factors bound to ETS-A in electrophoretic mobility shift assay (EMSA) (Figure 2B and data not shown), Etv2 displayed the strongest binding (Figure 2B). We also identified a second ETS site within Mef2c F10-44 (ETS-B), which was also bound by several distinct Ets proteins in EMSA, including Etv2 (data not shown). A third potential core ETS-binding site (TTCC) in F10-44, located between ETS-A and ETS-B, was not bound in EMSA by Etv2 or the Ets-1 DNA-binding domain (DBD) under conditions in which the control ETS site, ETS-A, and ETS-B were each robustly bound (data not shown).

In addition to the ETS sites, the footprinting studies showed an additional endothelial-specific activity immediately adjacent to the ETS-A site (Figure S2). This adjacent sequence had weak similarity to the core Forkhead binding site RYMAAYA (Carlsson and Mahlapuu, 2002), so we performed EMSA to determine whether the footprinted region was bound by different subfamilies of Forkhead transcription factors (Figure 2C). Indeed, FoxC1 and FoxC2 bound robustly to this noncanonical Forkhead site (FOX-NC; Figure 2C, lanes 10-13), and this binding was disrupted by a 3 bp mutation within FOX-NC (Figure 2C, lanes 14-17), suggesting that these Forkhead proteins bind to a broader consensus site than previously thought. FoxO1 also bound to the FOX-NC site, albeit less robustly than FoxC1 or FoxC2 (Figure 2C, lanes 8-9). FoxA2, FoxF1, and FoxH1 did not display any detectable binding to FOX-NC in EMSA (Figure 2C, lanes 2–7), although each protein was efficiently synthesized in vitro and each bound to its own canonical site in the same assay (Figure S3). In addition, we performed chromatin immunoprecipitation (ChIP) analyses on primary mouse embryo fibroblasts transfected with an epitope-tagged FoxC2 construct, which demonstrated that FoxC2 could bind to the endogenous F10-44 enhancer in vivo (Figure 2D). No binding of FoxC2 protein was detected in ChIP analyses of the skeletal muscle-specific *myogenin* promoter, which served as a nonspecific control (Figure 2D).

Next, we tested the ability of FoxC and Ets transcription factors to activate the F10E enhancer (Figure 2E). Alone, FoxC2 and Etv2 activated the *Mef2c* F10E enhancer 3-fold and 7-fold, respectively (Figure 2E, lanes 2 and 3). Strikingly, the combination of the two factors resulted in more than 40-fold synergistic activation (Figure 2E, lane 4). A 3 bp mutation that disrupted the binding of Etv2 and FoxC2 to the FOX:ETS motif in EMSA resulted in nearly complete disruption of transactivation (Figure 2E, lane 8), demonstrating the specificity of this activation.

The strong synergistic activation of the Mef2c F10E enhancer by FoxC2 and Etv2, combined with the immediate juxtaposition of the two binding sites, suggested that the two factors might be simultaneously binding to the FOX:ETS motif to activate transcription. To determine if FoxC2 and Etv2 bound to the FOX:ETS motif simultaneously, EMSA were performed in which increasing amounts of FoxC2 were added to a constant amount of Etv2 and the Mef2c F10-44 FOX:ETS motif (Figure 2F). As expected, Etv2 bound the FOX:ETS motif in the absence of FoxC2 (Figure 2F, lane 5). Addition of FoxC2 to the binding reactions resulted in the presence of probe bound solely by FoxC2 and in the formation of a complex of Etv2, FoxC2, and the FOX:ETS motif (Figure 2F, lanes 6-8). The slower mobility band suggests that FoxC2 and Etv2 form a ternary complex that requires both proteins and DNA. The ternary complex increased in abundance with increasing quantities of FoxC2 relative to Etv2 even in the presence of large amounts of excess free probe (Figure 2F, lanes 6-8). These results support the notion that FoxC2 and Etv2 cooccupy the FOX:ETS motif simultaneously and suggest that the two proteins may function together as part of a ternary complex to synergistically activate transcription.

To define the role of the FOX:ETS motif in vivo, we introduced a 3 bp mutation into this element in the context of the full-length 5.6 kb F10 fragment and used this mutant construct to generate transgenic mouse embryos (Figure 2G). *Mef2c* F10 contains both the F10E endothelial and F10N neural crest enhancers (Figure 1A). Disruption of the FOX:ETS motif resulted in a complete loss of endothelial activity, while neural crest activity was unperturbed (Figure 2G, F10 mutFEM). In addition, mutation of the second ETS site within F10-44 also resulted in a disruption of endothelial activity of the full-length F10 enhancer, while leaving neural crest activity undisturbed (Figure 2G, F10 mutETS-B).

Expression of FoxC2 and Etv2 in *Xenopus* Embryos Induces Ectopic Vascular Gene Expression

To test whether FoxC2 and Etv2 were sufficient to induce endothelial-specific gene activation more generally, we coinjected mRNAs for FoxC2 and Etv2 into a single cell at the vegetal pole of *Xenopus* embryos at the 4-cell stage (Figure 3). Remarkably, the two factors potently induced endothelial-specific gene expression in a normally avascular region of the endoderm in the tail region of the frog tadpole. In embryos injected with FoxC2 and Etv2, multiple regions of *flk1* mRNA expression were readily



Figure 2. Identification of a Novel FOX:ETS Motif Simultaneously Bound and Synergistically Activated by FoxC2 and Etv2

(A) Alignment of the mouse and zebrafish *Mef2c* F10-44 sequences. Red boxes denote core ETS-binding sites, and the blue box denotes a nonconsensus Forkhead-binding element (FOX-NC). The novel, composite FOX:ETS motif is indicated above. Consensus Forkhead- and Ets-binding sites (Hollenhorst et al., 2007; Carlsson and Mahlapuu, 2002) are denoted, as is the mutant FOX:ETS sequence used in these studies.

(B) Radiolabeled oligonucleotide probes encompassing the F10-44 ETS-A site were used in EMSA with recombinant Ets proteins. The Ets1 DNA-binding domain (DBD) and Etv2 efficiently bound to the site (lanes 2 and 11) and were competed by excess unlabeled self probe (wt, lanes 3 and 12) but not by mutant self-probe (mu, lanes 4 and 13). Erg and Elf-1 displayed little or no detectable binding to ETS-A in this assay.

(C) A radiolabeled oligonucleotide probe encompassing the *Mef2c* F10-44 FOX-NC site was used in EMSA with recombinant Forkhead proteins. FoxA2, FoxF1, and FoxH1 showed weak or no binding to FOX-NC. FoxO1 (lanes 8 and 9) showed weak binding to FOX-NC. FoxC1 (lanes 10 and 11) and FoxC2 (lanes 12, 13; also lanes 14–17) exhibited robust binding. Addition of excess, unlabeled self-probe, indicated by a + sign, inhibited binding of FoxO1, FoxC1, and FoxC2 to the FOX-NC site (lanes 9, 11, and 13). Additionally, inclusion of a mutant version of FOX-NC (lane 17, mu) did not inhibit binding of FoxC2 to FOX-NC at the same concentration that the wild-type self-probe completely abolished binding (lane 16, wt).

observed in nearly all embryos examined (Figure 3B). By contrast, injection of control mRNAs resulted in no induction of *flk1* expression (Figure 3A). Quantification of *flk1* expression in the abdominal region of injected frog embryos by real-time PCR showed that FoxC2 and Etv2 were each able to weakly induce the expression of *flk1*, while the combined expression of the two factors resulted in a synergistic level of activation of *flk1* expression more than 25-fold higher than in control injected embryos (Figure 3C). Coexpression of FoxC2 and Etv2 in *Xenopus* embryos also resulted in strong synergistic and ectopic activation of *Pecam* expression (Figure 3D). These results demonstrate that FoxC2 and Etv2 are sufficient to induce the expression of endogenous endothelial genes in vivo.

The Combined Functions of FoxC and Ets Proteins Are Required for Vascular Development in Zebrafish

Consistent with the deep conservation of F10-44, the mouse *Mef2c* F10E enhancer directed the expression of a GFP transgene in a vascular-specific manner in zebrafish at 48 hr postfertilization (hpf) (Figures 4A and 4B). Indeed, the expression directed by *Mef2c* F10E was nearly identical to the GFP expression observed in the *Tg(flk1:GFP)*^{s843} line, which is specific to endothelial cells at 48 hpf (Jin et al., 2005) (Figures 4C and 4D). These observations indicate that the transcriptional pathways governing endothelial cell gene expression in zebrafish utilize the same *cis*-elements as in the mouse, supporting the notion that the same transcriptional requirements are involved in endothelial enhancer regulation in the two organisms.

The orthologs of mammalian Ets factors are essential for vascular development in zebrafish (Pham et al., 2007; Sumanas and Lin, 2006), but the involvement of FoxC proteins in this process has not been described in zebrafish. We first examined the expression pattern of the zebrafish FoxC orthologs *foxc1a* and *foxc1b* (Topczewska et al., 2001). Both genes were expressed in the vasculature during the early stages of vascular development, including in the coalescing endothelial cells of the axial vessels at 24 hpf (Figures 4E–4H). We next tested the requirement of foxc genes in zebrafish by morpholino knockdown (Figures 4I-4L). Control morpholino-injected embryos displayed normal vascular development, which could be observed by the expression of Tg(flk1:GFP)^{s843} and normal accumulation of blood in the heart, as evidenced by the expression of Tg(gata1:DsRed)^{sd2} (Figure 4I). Knockdown of foxc1a resulted in a decrease in intersomitic vessel sprouting, although the trunk vasculature still formed (Figure 4J). Knockdown of foxc1b using a similar concentration of morpholino had a less profound effect on vascular development at 24 hpf (Figure 4K). Importantly, combinatorial knockdown of both proteins resulted in a more severe vascular phenotype. No intersomitic vessel sprouts were detected at 24 hpf, and the formation of the axial vessels was severely diminished (Figure 4L). These data suggest that FoxC proteins are required for vascular development in zebrafish.

In previous studies, it was noted that high-concentration morpholino knockdown of single ets genes had some effect on vascular development in the fish, most notably with etsrp (ets1b), the zebrafish ortholog of Etv2 (Pham et al., 2007; Sumanas et al., 2008; Sumanas and Lin, 2006). However, injection of a low dose of etsrp morpholino (0.5 ng) resulted in no discernable phenotype at 24 hpf (Figure 4O). Similarly, injection of a lower dose of foxc1a morpholino (4 ng) than that used in the experiments shown in Figure 4J resulted in little or no vascular phenotype at 24 hpf (Figure 4N). Remarkably, coinjection of the same subphenotypic doses of etsrp and foxc1a morpholinos resulted in a nearly complete ablation of vascular development, as indicated by dramatically reduced Tg(flk1:GFP)^{s843} expression (Figure 4P). Since the *flk1-gfp* construct used to visualize the vasculature may itself be a direct target of FoxC1a and Etsrp, we also used the *Tg(gata1:DsRed)*^{sd2} line to visualize blood cells. Consistent with failed circulation due to severely disrupted vascular development, we observed massive pooling of blood in the tail in the double morpholino-injected embryos (Figure 4P). These results provide additional strong support for an essential role for FoxC and Ets factors in vascular development.

⁽D) Chromatin immunoprecipitation from mouse embryo fibroblasts transfected with pCDNA3.1-FoxC2-Flag (C2) or parental pCNA3.1 expression vector (ctrl). Sheared, crosslinked chromatin fragments were immunoprecipitated with anti-FLAG antibody and the region of the endogenous *Mef2c* locus, surrounding F10-44, was amplified by PCR (upper panel). As a control, the region surrounding the *myogenin* skeletal muscle promoter was amplified by PCR (lower panel). The *Mef2c* F10-44 region was specifically amplified in pDNA3.1-FoxC2-FLAG transfected cells (lane 5), similar to the amplification in control samples that were directly amplified without prior immunoprecipitation (input, lanes 1 and 3). No amplification was detected in control transfected (lane 2) or nonspecific lgG immunoprecipitated samples (lane 4). The *myogenin* promoter was not amplified in pCDNA3.1-FoxC2-FLAG transfected cells under conditions in which the *Mef2c* F10-44 region was amplified (lower panel, lane 5).

⁽E) FoxC2 and Etv2 synergistically *trans*-activate the *Mef2c* F10E enhancer. FoxC2 and Etv2 each weakly activated the reporter (lanes 2 and 3) compared to parental expression plasmid control transfections (lane 1). Cotransfection of the reporter with expression plasmids for FoxC2 and Etv2 together resulted in potent synergistic activation (lane 4). Mutation of the FOX:ETS motif (mutFEM) ablated activation by FoxC2 and Etv2 (lanes 5–8). Data are presented as the mean fold activation for four independent sets of transfections and analyses. Error bars indicate the standard error of the mean (SEM).

⁽F) FoxC2 and Etv2 simultaneously bind the FOX:ETS motif. A radiolabeled oligonucleotide probe (*Mef2c*-F10 FOX:ETS) encompassing only the F10E FOX:ETS motif was used in EMSA with recombinant FoxC2 and Etv2. The labeled probe included the FOX:ETS motif plus short adjacent sequences and did not include additional potential ETS-binding sites. Increasing amounts of FoxC2 in the absence of Etv2 resulted in the formation of an increasing amount of FoxC2-DNA complex (lanes 2–4). Addition of Etv2 alone resulted in the formation of an Etv2-DNA complex (lane 5). Addition of increasing amounts of FoxC2 in the presence of a constant amount of Etv2 resulted in formation of each individual protein-DNA complex as well as a slower mobility band, suggesting a FoxC2-Etv2-DNA ternary complex (lanes 6–8). Relative levels of FoxC2 and Etv2 protein and binding activity are indicated at the top of the panel. In all samples, the total amount of total protein was held constant by the addition of the appropriate amount of unprogrammed reticulocyte lysate.

⁽G) A 3 bp mutation (CATAACAGGAA to CATAtCtaGAA) of the FOX:ETS motif (mutFEM) or mutation of the ETS-B site in the context of *Mef2c* F10, which contains both neural crest and endothelial enhancers, results in loss of transgene expression in the endothelium but not the neural crest. The resultant transgenic embryos show expression patterns similar to those in which the entire 44 bp element was deleted from F10 (*Mef2c* F10 Δ 44). Representative transgenic embryos from each construct are shown.



Figure 3. Misexpression of FoxC2 and Etv2 in *Xenopus* Embryos Induces Ectopic Endothelial Gene Expression

Xenopus embryos were injected with mRNAs encoding FoxC2 and Etv2 or EGFP control mRNA at the 4-cell stage and then collected at stage 36. After collection, embryos were either assayed by in situ hybridization using *flk1* probe, followed by sectioning (A and B), or RNA was extracted for qPCR analysis of *flk1* (C) or *Pecam* (D) transcripts. (A and B) *flk1* expression was observed in the cardinal veins (CVs) in control (A) and FoxC2 + Etv2-injected (B) embryos. In addition, ectopic expression of *flk1* was readily observed in the endoderm of the caudal region of FoxC2 + Etv2-injected embryos (B) but not in EGFP control injected embryos (A).

(C and D) Quantitative, real-time PCR shows that neither FoxC2 nor Etv2 significantly activated *flk1* or *Pecam* expression on their own, but the combination of the two factors strongly induced expression of both endothelial-specific markers. Data are shown as the mean relative expression of *flk1* or *Pecam* transcripts for three independent sets of injections and analyses. Error bars indicate the SEM.

The FOX:ETS Motif Is Present in Many Endothelial-Specific Enhancers

The combined requirement for FoxC and Ets factors in vascular development suggested that other endothelial-specific enhancers besides *Mef2c* F10E might also contain similar FOX:ETS motifs and be direct transcriptional targets of FoxC2 and Etv2. An examination of previously identified endothelial-specific enhancer elements revealed the presence of FOX:ETS motifs, including similar noncanonical Forkhead sites, in the *FLK1*, *TIE2*, *TAL1* (SCL), *NOTCH4*, and *VE-CADHERIN* (*CDH5*) en-

hancers (Figure 5A) (Dube et al., 1999; Gottgens et al., 2002; Kappel et al., 1999; Prandini et al., 2005; Wu et al., 2005). Similar to the *Mef2c* FOX:ETS motif, each of the elements was bound robustly and specifically by FoxC2 and Ets in EMSA, and mutations within each of the FOX:ETS motifs abolished binding (Figure 5C). ChIP analyses demonstrated that the enhancer regions of each of these additional genes were bound by FoxC2 in vivo (Figure 5B).

Next, we tested whether the *Flk1*, *Tie2*, *Tal1*, *NOTCH4*, and *VE-CADHERIN* enhancers were synergistically activated by the combinatorial action of FoxC2 and Etv2 in transfection analyses (Figure 6). In all cases, FoxC2 and Etv2 by themselves only weakly activated the enhancers. However, in combination, the two transcription factors caused synergistic activation of the enhancers (Figures 6A–6E, lanes 1–4). Furthermore, mutation of the FOX:ETS motif in the *VE-CADHERIN* enhancer disrupted activation by FoxC2 and Etv2 in *trans*-activation assays (Figure 6E, lanes 5–8) and completely abolished endothelial-specific expression of *lacZ* in transgenic embryos (Figures 6F and 6G).

The Presence of a FOX:ETS Motif Is Sufficient to Identify Novel Endothelial-Specific Enhancers

The observation that multiple, well-established endothelial-specific enhancers contained functional FOX:ETS motifs suggested that this element might be present in many enhancers of genes expressed in the endothelium. To determine if the FOX:ETS motif was overrepresented within endothelial cell-expressed gene loci, we performed a computational screen to search for the presence of a FOX:ETS motif and a second ETS site within 60 bp (Figure 7). We included the requirement for a second core ETS-binding site $(GGA^{A}/_{T})$ as part of our computational screen since a second ETS site was found within 60 bp of the FOX:ETS motif in all of the enhancers listed in Figure 5A. Figure 7A shows a sequence logo representation of the position weight matrix used as the FOX:ETS consensus motif. Our computational screen identified the FOX:ETS motif within all six regulatory elements shown in Figure 5A, which served as an important validation of the computational parameters of the screen. We identified 445 deeply conserved FOX:ETS motifs with a neighboring equally conserved second ETS site in the human genome. When the search was conducted such that the second ETS site only had to be conserved between mouse and human, 1500 FOX:ETS motifs, associated with 1200 genes, were identified.

We compared the distribution of positive hits from this screen in three predetermined sets of genes: 69 known endothelial cellexpressed genes, 305 housekeeping genes, and 75 skeletal muscle-expressed genes (Table S1). We observed a highly significant enrichment of the FOX:ETS motif and second ETS site in the endothelial gene set compared to the housekeeping and skeletal muscle gene sets (Figure 7B; $p < 10^{-8}$). There was also a slight enrichment for hematopoietic genes, which were identified at 23% of the frequency of endothelial genes (150/445 endothelial versus 35/445 hematopoietic). Some association of the FOX:ETS motif with hematopoietic genes was expected given the numerous genes that are coexpressed in blood and endothelial cells and the likely existence of a common progenitor cell for the two lineages (Baron, 2003). Taken together, our



Figure 4. Combinatorial Regulation of Vascular Development in Zebrafish by FoxC and Ets Proteins

(A–D) The mouse *Mef2c* F10E enhancer directs expression of the GFP reporter gene in the vascular endothelium of transgenic zebrafish (A and B) in a nearly identical pattern to the endothelial-specific *Tg(fik1:GFP)*^{s843} reporter (C and D).

(E–H) In situ hybridization shows that the zebrafish *foxc* genes *foxc1a* (E and F) and *foxc1b* (G and H) are expressed in the developing vasculature at 24 hpf. (I–L) Knockdown of *foxc1a* and *foxc1b* by morpholino injection alone (J and K) and in combination (L) resulted in loss of vascular structure, as detected by reduced expression of *Tg(flk1:GFP)*^{s843} (green) and the pooling of blood, as indicated by *Tg(gata1:DsRed)*^{sd2} expression (red). The combined *foxc1b* knockdown (L) resulted in a more severe perturbation of vascular development than either single knockdown. Note the normal expression of *Tg(flk1:GFP)*^{s843} and *Tg(gata1:DsRed)*^{sd2} in the control morpholino-injected embryo (I).

(M–P) Injection of subphenotypic doses of *foxc1a* (N) and *etsrp* (O) morpholinos resulted in normal vascular development and normal expression of *Tg(flk1:GFP)*^{s843} and *Tg(gata1:DsRed)*^{sd2} in patterns identical to control injected embryos (M). Coinjection of the lower doses of *foxc1a* and *etsrp* morpholinos resulted in a nearly complete loss of vascular development (P). Asterisks mark the pooling of blood. Arrowheads point to the developing axial vessels, and arrows indicate the developing intersomitic vessels.

observations support the idea that the FOX:ETS motif is a common feature of many endothelial-specific genes and that its presence might be used to identify endothelial-specific enhancers and genes computationally.

As an initial test to determine if the presence of the FOX:ETS motif was sufficient to identify vascular enhancers, we investigated the FOX:ETS regions identified in our computational screen within 13 genes expressed in endothelial cells (Table S2). EMSA analyses demonstrated that 10 of the 13 FOX:ETS motifs were bound by FoxC2 and Etv2 proteins in vitro (data not shown). Among the 10 regions validated by EMSA, we tested eight for enhancer function in transgenic mouse embryos. In each case, a region of approximately 1 kb encompassing the FOX:ETS motif was tested in transient transgenic reporter assays for enhancer activity in mice at E9.5. Among the eight fragments tested, five functioned as endothelial-specific enhancers in transgenic embryos (Figure 7C). The five enhancers identified using this approach, from the human FLT4 (VEGFR3), PDGFRβ, ECE1, NRP1, and FOXP1 genes, were all novel and none demonstrated extensive sequence conservation beyond the FOX:ETS motif and second ETS site, such that depth of sequence conservation alone would not have predicted these bona fide endothelial enhancers. Thus, these studies indicate the importance of the FOX:ETS motif as a predictive tool for the unbiased identification of endothelial enhancers based on its presence.

DISCUSSION

Induction of Endothelial Gene Expression by the Combinatorial Action of Forkhead and Ets Factors

It is well established that members of the Ets transcription factor family are involved in the development of the endothelium, but the mechanism by which they contribute to the specificity of endothelial gene expression has been a key conundrum in vascular biology since no Ets factor is unique to the vasculature (Hollenhorst et al., 2004; Maroulakou and Bowe, 2000). In this paper, we discovered that Ets factors function in combination with FoxC proteins, which are also not restricted to the vasculature (Carlsson and Mahlapuu, 2002; Dejana et al., 2007). It is likely



Figure 5. The FOX:ETS Motif Is Present in Multiple Endothelial Enhancers

(A) Sequence and genomic location of FOX:ETS motifs in MEF2C and five other known endothelial-specific regulatory elements. The ETS sites are highlighted in red, and the FOX-NC sites are highlighted in blue. Chromosome locations refer to the May 2004 assembly of the human genome. (B) ChIP from primary mouse embryo fibroblasts transfected with pCDNA3.1-FoxC2-FLAG (C2) or parental pCDNA3.1 expression vector (ctrl) shows that FoxC2 binds to the FOX:ETS motif in the endogenous endothelial enhancers of the orthologous mouse genes. Human gene names are shown. In each case, the FOX:ETS motif is perfectly conserved. In each case, the enhancer regions were specifically amplified in pDNA3.1-FoxC2-FLAG transfected cells (lane 5), similar to the amplification in control samples that were directly amplified without prior immunoprecipitation (input, lanes 1 and 3). No amplification was detected in control transfected (lane 2) and nonspecific IgG immunoprecipitated samples (lane 4). Note that these reactions were performed in conjunction with the ChIP for the myogenin promoter region, shown in Figure 2D, which also serves as a nonspecific control for these endogenous aenes.

(C) EMSA demonstrates that FoxC2 (lanes 2, 8, 14, 20, and 26) and Ets1 DBD (lanes 5, 11, 17, 23, and 29) bind directly to the FOX:ETS motifs present in *FLK1*, *TEK* (*Tie2*), *TAL1*, *NOTCH4*, and *CDH5* (*VE-CADHERIN*). In each case, an excess of unlabeled FOX:ETS motif self-probe (wt) efficiently competed for binding of FoxC2 and Ets1 DBD. Small mutations within the FOX-NC site (mu) disrupted competition by unlabeled probes even when added in $50 \times$ excess (lanes 4, 10, 16, 22, and 28).

that several members of the Forkhead and Ets transcription factor families may be involved in vascular regulation via the FOX: ETS motif. In addition to Etv2, other Ets factors activated enhancers containing the FOX:ETS motif and induced ectopic vascular gene expression in *Xenopus* in concert with FoxC (data not shown). *Foxc1/Foxc2* compound null mice have severe vascular defects (Seo et al., 2006), and we show here that combined knockdown of the two *foxc* genes in zebrafish also severely disrupts vascular development. However, some endothelial specification clearly still occurs in both fish and mice lacking FoxC function, supporting a possible role for other Forkhead proteins. Consistent with this notion, the *Mef2c* FOX:ETS motif was also bound by FoxO1 in the studies presented here, and *Foxo1* null mice die by E10.5 with incomplete vascular development (Furuyama et al., 2004; Hosaka et al., 2004).

Tissue-Specific Enhancer Prediction Based on the Presence of a Signature *cis*-Acting Element

The haploid human genome contains nearly 3 billion base pairs, but only about 1.5% of this sequence is protein encoding. Much of the non-protein-encoding sequence has been conserved for hundreds of millions of years and performs many functions, including regulation of gene expression. However, the ability to predict functional regulatory elements within vertebrate genomes based solely on sequence information is poor. Enhancer elements have been accurately predicted in mammalian genomes only by screening for large numbers of different binding motifs or by using extreme levels of conservation (Hallikas et al., 2006; Pennacchio et al., 2006). Our recent use of deep phylogenetic conservation to identify enhancers successfully defined numerous regulatory elements, but interestingly, these studies did not identify a single enhancer directing expression to the vasculature, suggesting that using sequence conservation between species alone was not an effective approach to identify endothelial enhancers (Pennacchio et al., 2006).

The identification of a 44 bp enhancer from *Mef2c* that alone is sufficient to direct endothelial-specific expression is unprecedented with regard to its small size and allowed us to identify the FOX:ETS motif, a composite *cis*-acting element essential for enhancer function in vivo. Interestingly, although the most highly conserved 44 bp of *Mef2c* F10E (F10-44) was sufficient to direct endothelial-specific expression throughout early embryogenesis,



Figure 6. FoxC2 and Etv2 Synergistically Activate Multiple Endothelial Enhancers

(A–E) FoxC2 and Etv2 synergistically *trans*-activate the *Flk1* (A), *Tie2* (B), *Tal1* (C), *NOTCH4* (D), and *VE-CADHERIN/CDH5* (E) enhancers. Data are presented as the mean fold activation for three to six independent sets of transfections and analyses. Error bars indicate the SEM. Note that in (E), a 4 bp mutation in the FOX: ETS motif (mutFEM) completely abolished activation of the *VE-CADHERIN* promoter/enhancer by FoxC2 and Etv2.

(F and G) Mutation of the FOX:ETS motif within the 3.5 kb VE-CADHERIN promoter/enhancer completely disrupts VE-CADHERIN-lacZ transgene expression at E9.5 (G) when compared to the strong, vascular-specific expression of the wild-type transgene (F). All five embryos transgenic for the wild-type 3.5 kb VE-CADHERIN enhancer expressed lacZ robustly in the endothelium, while none of the three embryos transgenic for the mutated enhancer showed detectable expression.

the activity of this small enhancer was extinguished after E10.5. By contrast, the larger 900 bp F10E construct remained active exclusively in endothelial cells of both the blood and lymphatic vasculature throughout embryogenesis and in adulthood (data not shown). It is important to note that the 900 bp F10E construct still required an intact FOX:ETS motif for activity at later stages in development. These data suggest that additional *cis*-acting elements are involved in endothelial-specific maintenance of the larger enhancer fragment and support a model in which the FOX:ETS motif serves as an ancient, endothelial-specific initiation element to which additional complexity has been added throughout evolution. Consistent with this notion, there is exten-

sive homology within *Mef2c* F10E beyond the FOX:ETS motif, although the cross-species homology is not as deep as the FOX:ETS motif (Figure S4). Furthermore, additional complexity may have been added to the FOX:ETS motif in enhancers with activity that restricts to distinct endothelial compartments, such as arteries, veins, and lymphatics. Testing additional putative enhancers in transgenic mice should allow for the identification of other *cis*-motifs that are overrepresented in endothelial enhancers and are associated with the FOX:ETS motif. In addition, these studies may establish a model for enhancer prediction that may be applicable to any lineage or sublineage once there is adequate understanding of required *cis*-elements.

Gene Set FOX:ETS Motifs/ Gene Set FOX:ETS Motifs/ 100 Genes FOX:ETS Motifs/ FOX:ETS Moti	4				в			
Endothelial Genes 27.5 23.1% Housekeeping Genes 2.6 2.6%	2 ₁					Gene Set	FOX:ETS Motifs/ 100 Genes	Genes with a FOX:ETS Moti
APANVNVNA Housekeeping Genes 2.6 2.6%	;음 1-	A	ΛΛΛ			Endothelial Genes	27.5	23.1%
5'-1 2 3 4 5 6 7 8 9 10 11 3'	0	<u>A</u>		UU A A		Housekeeping Genes	2.6	2.6%
position Skeletal Muscle Genes 0 0%	5'-1	234	5 6 7 position	8 9 10 11 -	.3′	Skeletal Muscle Genes	0	0%



Figure 7. Prediction of Endothelial-Specific Enhancers Based on the Presence of a FOX:ETS Motif

(A) Sequence logo representing the position weight matrix of the consensus FOX:ETS motif used in a genome-wide scan.

(B) The FOX:ETS motif is overrepresented in endothelial genes when compared to housekeeping and skeletal-muscle-expressed genes.

(C) Identification of five novel endothelial-specific enhancers from the whole-genome screen based on the presence of a FOX:ETS motif. The upper row of photos shows representative whole-mount X-gal-stained transient transgenic embryos at E9.5 from the *ECE1*, *FLT4*, *PDGFRβ*, *NRP1*, and *FOXP1* genes. Each directed strong *lacZ* expression specifically to the endothelium, which can be clearly seen in transverse sections taken from each of the transient transgenic analyses at E9.5 (lower row of photos). CV, cardinal vein; DA, dorsal aorta; hrt, heart; LV, left ventricle; NT, neural tube; RV, right ventricle; SV, sinus venosus.

The Fox-Ets Interaction as a Target for Modulation of Vascular Growth and Remodeling

Aberrant vessel growth is an important contributor to several prevalent disease states (Carmeliet and Jain, 2000). Improper overgrowth of blood vessels is an important cause of age-related macular degeneration, and neovascularization of the retina is the hallmark of proliferative diabetic retinopathy (Andreoli and Miller, 2007; Simo et al., 2006). Likewise, growth and metastasis of solid tumors requires an adequate blood supply, and angiogenic induction of new blood vessel growth into tumors is an important component of cancer pathology (Stacker et al., 2002). Current strategies to inhibit angiogenesis are primarily based on blocking vascular endothelial growth factor (VEGF) signaling (anti-VEGF therapy), and the use of a monoclonal antibody against VEGF has been shown to be clinically effective when used in combination with other chemotherapeutic agents (Goh et al., 2007). However, drug resistance of metastatic tumors is a concern, and the identification of additional targets for blocking vessel growth remains an important goal for cancer therapy (Goh et al., 2007). The observation that the FOX:ETS motif is strongly associated with numerous endothelial genes in the human genome suggests that blocking activation via the FOX:ETS motif might sufficiently inhibit the endothelial transcriptional program to serve as a novel target for therapeutic intervention in cancer and other diseases involving aberrant vessel growth.

EXPERIMENTAL PROCEDURES

Plasmids, Cloning, and Mutagenesis

The 5550 bp F10 fragment from *Mef2c* was generated by PCR and cloned into the transgenic reporter plasmid HSP68-*lacZ* (De Val et al., 2004). F10-44 was created by cloning complementary oligonucleotides, corresponding to the 44 bp deeply conserved F10 sequence, into HSP68-*lacZ*. The mouse *flk1*, mouse *Tie2*, and human *NOTCH4* enhancers were generated by PCR from genomic DNA and cloned into p-TK- β -gal. The *Tal1* (SCL +19) enhancer, which has been described (Gottgens et al., 2002), was subcloned into p-TK- β -gal. The 3564 bp and 377 bp *VE-CADHERIN* promoter/enhancer fragments were generated by PCR from human genomic DNA and cloned into the promoterless *lacZ* reporter plasmid p-AUG- β -gal for the generation of transgenic mice and for use in transfection assays. The *FLT4*, *FOXP1*, *NRP1*, *ECE1*, *PDGFR* β , *NR4A3*, *EFNB1*, and *FGFR2* enhancers were amplified from human genomic DNA by PCR and cloned into HSP68-*lacZ*.

For zebrafish transgenesis, the 885 bp *Mef2c* F10E enhancer fragment was cloned upstream of an *HSP70-GFP* cassette. For generating *foxc1a* and *foxc1b* in situ probes, 800 bp at the 3' end of these genes including the 3' UTR were PCR amplified. The *Xenopus flk1* in situ probe has been described previously (Cleaver et al., 1997). Expression plasmids were generated by cloning cDNAs into plasmid pRK5.

Oligonucleotides and Morpholino Oligonucleotides

The sequences of oligonucleotide primers for cloning, mutagenesis, morpholino knockdowns, qPCR detection of *Xenopus laevis Pecam* and *flk1*, and ChIP detection are provided in Table S3. Oligonucleotide primer sequences used in EMSA are provided in Table S4. The morpholino oligonucleotides for *etsrp*, *foxc1a*, and *foxc1b* have been described previously (Pham et al., 2007; Top-czewska et al., 2001).

Mice, Frogs, and Zebrafish

Transgenic mice were generated by oocyte microinjection, and genotype analysis and X-gal staining were performed as described previously (De Val et al., 2004). Zebrafish whole-mount in situ hybridization was performed as previously described (Jin et al., 2005). To generate *Mef2c*-GFP transgenic zebrafish, embryos were injected with 20–50 ng of construct at the one-cell stage and analyzed at 24–48 hpf. Morpholino analyses were performed in *Tg(fik1:GFP)*^{s843}; *Tg(gata1:DsRed)*^{sd2} embryos (Jin et al., 2005; Traver et al., 2003). Embryos of the frog *Xenopus laevis* were microinjected and incubated as described previously (Cleaver et al., 1997). RNA encoding EGFP was included in all injections as a lineage tracer. Transcript levels for *flk1* and *Pecam* were assayed by qRT-PCR using normalized samples and SYBR-Green (Invitrogen). All experiments using animals complied with federal and institutional guidelines.

Cell Culture, Transfections, and Chromatin Immunoprecipitation

For transient transfection assays, Cos1 cells were grown in DMEM supplemented with 10% FBS and seeded at 6 × 10⁴ cells/2.5 cm plate. After 24 hr, 750 ng each of reporter and expression plasmids were transfected using FuGENE6 (Roche) as recommended by the manufacturer. All transfections lacking an expression plasmid contained an equal amount of the parental expression vector. Following transfection, cells were cultured for 48 hr, then harvested and assayed using the Luminescent β -galactosidase Detection kit II (Clontech), as previously described (Rojas et al., 2008).

For ChIP, primary mouse embryo fibroblasts (MEFs) were transfected using Lipofectamine LTX and 8 μ g of either pcDNA3.1-FLAG-FoxC2 or empty pCDNA3.1 vector in 10 cm dishes. Thirty-six hours after transfection, cells were harvested as described previously (Rojas et al., 2008). ChIP was then performed using the ChIP assay kit (Upstate/Millipore) according to the manufacturer's instructions, using anti-FLAG antibody (clone M2, Sigma) and protein A-agarose. Immunoprecipitated fragments and unprecipitated lysates (input samples) were subjected to PCR using primers listed in Table S3.

Electrophoretic Mobility Shift Assay

Electrophoretic mobility shift assay (EMSAs) were performed as described previously (De Val et al., 2004). All recombinant proteins were generated using the TNT Quick Coupled Transcription/Translation System (Promega) according to the manufacturer's instructions. Full-length FoxC1, FoxC2, FoxA2, FoxF1, FoxH1, Erg1, and Etv2 were expressed from either pCS2 or pcDNA3 expression plasmids using SP6 polymerase. FoxF1, FoxO1, Elf-1, and the Ets1 DBD (De Val et al., 2004) were expressed from the pCITE2A in vitro expression vectors, using T7 polymerase (Novagen).

Identification of Conserved Sequence Motifs

The sequences within and 10 kb around all human genes in the RefSeq database (Pruitt et al., 2005) were scanned utilizing rVista (Loots et al., 2002). The position weight matrix for the FOX:ETS motif, which was derived from the six FOX:ETS sequences shown in Figure 5A plus 11 additional FOX:ETS motifs identified experimentally as bound by FoxC2 and Etv2 in EMSA, and a second consensus ETS site were used to scan mouse and human gene sequences independently. Hits in which the depth of conservation of the FOX:ETS motif was less than the surrounding 20 bp of sequence were discounted, as were those in which the depth of conservation of the second ETS site was not equal to that of the FOX:ETS motif.

SUPPLEMENTAL DATA

Supplemental Data include four figures and four tables and can be found with this article online at http://www.cell.com/supplemental/S0092-8674(08)01387-1.

ACKNOWLEDGMENTS

We thank Peter Oettgen, Bertie Gottgens, Ralph Janknecht, Tom Kume, Robert Costa, and Deepak Srivastava for providing plasmids for these studies; Brant Weinstein for providing Ets morpholinos; Saleh Adi for advice and plasmids; Shaun Coughlin for comments on the manuscript; and Dan Palmer for assistance with MEF culture. S.D.V. was supported in part by a postdoctoral fellowship from the American Heart Association, Western States Affiliate. N.C.C. was supported by a K08 award from the NIH and a Fellow-to-Faculty award from the American Heart Association. This work was supported by NIH grants HL64658 to B.L.B. and HL54737 to D.Y.R.S., by a grant from the Sandler Family Supporting Foundation to B.L.B., and under Department of Energy Contract DE-AC02-05CH11231 to L.A.P.

Received: April 14, 2008 Revised: August 20, 2008 Accepted: October 20, 2008 Published: December 11, 2008

REFERENCES

Andreoli, C.M., and Miller, J.W. (2007). Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr. Opin. Ophthalmol. 18, 502–508.

Baron, M.H. (2003). Embryonic origins of mammalian hematopoiesis. Exp. Hematol. *31*, 1160–1169.

Carlsson, P., and Mahlapuu, M. (2002). Forkhead transcription factors: key players in development and metabolism. Dev. Biol. *250*, 1–23.

Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.

Cleaver, O., Tonissen, K.F., Saha, M.S., and Krieg, P.A. (1997). Neovascularization of the Xenopus embryo. Dev. Dyn. 210, 66–77.

De Val, S., Anderson, J.P., Heidt, A.B., Khiem, D., Xu, S.M., and Black, B.L. (2004). *Mef2c* is activated directly by Ets transcription factors through an evolutionarily conserved endothelial cell-specific enhancer. Dev. Biol. *275*, 424–434.

Dejana, E., Taddei, A., and Randi, A.M. (2007). Foxs and Ets in the transcriptional regulation of endothelial cell differentiation and angiogenesis. Biochim. Biophys. Acta *1775*, 298–312.

Dube, A., Akbarali, Y., Sato, T.N., Libermann, T.A., and Oettgen, P. (1999). Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. Circ. Res. *84*, 1177–1185.

Flamme, I., Frolich, T., and Risau, W. (1997). Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. *173*, 206–210.

Furuyama, T., Kitayama, K., Shimoda, Y., Ogawa, M., Sone, K., Yoshida-Araki, K., Hisatsune, H., Nishikawa, S., Nakayama, K., Nakayama, K., et al. (2004). Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J. Biol. Chem. 279, 34741–34749.

Goh, P.P., Sze, D.M., and Roufogalis, B.D. (2007). Molecular and cellular regulators of cancer angiogenesis. Curr. Cancer Drug Targets 7, 743–758.

Gottgens, B., Nastos, A., Kinston, S., Piltz, S., Delabesse, E.C., Stanley, M., Sanchez, M.J., Ciau-Uitz, A., Patient, R., and Green, A.R. (2002). Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. EMBO J. 21, 3039–3050.

Hallikas, O., Palin, K., Sinjushina, N., Rautiainen, R., Partanen, J., Ukkonen, E., and Taipale, J. (2006). Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell *124*, 47–59.

Hollenhorst, P.C., Jones, D.A., and Graves, B.J. (2004). Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. Nucleic Acids Res. *32*, 5693–5702.

Hollenhorst, P.C., Shah, A.A., Hopkins, C., and Graves, B.J. (2007). Genomewide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev. *21*, 1882–1894.

Hosaka, T., Biggs, W.H., 3rd, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., and Arden, K.C. (2004). Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. USA *101*, 2975–2980. Jin, S.W., Beis, D., Mitchell, T., Chen, J.N., and Stainier, D.Y. (2005). Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development *132*, 5199–5209.

Kappel, A., Ronicke, V., Damert, A., Flamme, I., Risau, W., and Breier, G. (1999). Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice. Blood 93, 4284–4292.

Lin, Q., Lu, J., Yanagisawa, H., Webb, R., Lyons, G.E., Richardson, J.A., and Olson, E.N. (1998). Requirement of the MADS-box transcription factor MEF2C for vascular development. Development *125*, 4565–4574.

Loots, G.G., Ovcharenko, I., Pachter, L., Dubchak, I., and Rubin, E.M. (2002). rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res. *12*, 832–839.

Maroulakou, I.G., and Bowe, D.B. (2000). Expression and function of Ets transcription factors in mammalian development: a regulatory network. Oncogene 19, 6432–6442.

Patan, S. (2004). Vasculogenesis and angiogenesis. Cancer Treat. Res. 117, 3–32.

Pennacchio, L.A., Ahituv, N., Moses, A.M., Prabhakar, S., Nobrega, M.A., Shoukry, M., Minovitsky, S., Dubchak, I., Holt, A., Lewis, K.D., et al. (2006). In vivo enhancer analysis of human conserved non-coding sequences. Nature 444, 499–502.

Pham, V.N., Lawson, N.D., Mugford, J.W., Dye, L., Castranova, D., Lo, B., and Weinstein, B.M. (2007). Combinatorial function of ETS transcription factors in the developing vasculature. Dev. Biol. *303*, 772–783.

Prandini, M.H., Dreher, I., Bouillot, S., Benkerri, S., Moll, T., and Huber, P. (2005). The human VE-cadherin promoter is subjected to organ-specific regulation and is activated in tumour angiogenesis. Oncogene *24*, 2992–3001.

Pruitt, K.D., Tatusova, T., and Maglott, D.R. (2005). NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res. 33, D501–D504.

Rojas, A., Kong, S.W., Agarwal, P., Gilliss, B., Pu, W.T., and Black, B.L. (2008). GATA4 is a direct transcriptional activator of Cyclin D2 and Cdk4 and is required for cardiomyocyte proliferation in anterior heart field-derived myocardium. Mol. Cell. Biol. *28*, 5420–5431.

Sato, Y. (2001). Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct. Funct. 26, 19–24.

Seo, S., Fujita, H., Nakano, A., Kang, M., Duarte, A., and Kume, T. (2006). The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev. Biol. 294, 458–470.

Simo, R., Carrasco, E., Garcia-Ramirez, M., and Hernandez, C. (2006). Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr. Diabetes Rev. 2, 71–98.

Stacker, S.A., Baldwin, M.E., and Achen, M.G. (2002). The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16, 922–934.

Sumanas, S., and Lin, S. (2006). Ets1-related protein is a key regulator of vasculogenesis in zebrafish. PLoS Biol. *4*, e10. 10.1371/journal.pbio.0040010.

Sumanas, S., Gomez, G., Zhao, Y., Park, C., Choi, K., and Lin, S. (2008). Interplay between Etsrp/ER71, scl and alk8 signaling controls endothelial and myeloid cell formation. Blood *111*, 4500–4510.

Topczewska, J.M., Topczewski, J., Solnica-Krezel, L., and Hogan, B.L. (2001). Sequence and expression of zebrafish foxc1a and foxc1b, encoding conserved forkhead/winged helix transcription factors. Mech. Dev. 100, 343–347.

Traver, D., Paw, B.H., Poss, K.D., Penberthy, W.T., Lin, S., and Zon, L.I. (2003). Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat. Immunol. *4*, 1238–1246.

Wu, J., Iwata, F., Grass, J.A., Osborne, C.S., Elnitski, L., Fraser, P., Ohneda, O., Yamamoto, M., and Bresnick, E.H. (2005). Molecular determinants of NOTCH4 transcription in vascular endothelium. Mol. Cell. Biol. 25, 1458–1474. Cell, Volume 135

Supplemental Data

Combinatorial Regulation of Endothelial

Gene Expression by Ets and Forkhead

Transcription Factors

Sarah De Val, Neil C. Chi, Stryder M. Meadows, Simon Minovitsky, Joshua P. Anderson, Ian S. Harris, Melissa L. Ehlers, Pooja Agarwal, Axel Visel, Shan-Mei Xu, Len A. Pennacchio, Inna Dubchak, Paul A. Krieg, Didier Y.R. Stainier, and Brian L. Black



Figure S1. Mef2c-null embryos display aberrant vascular development. (A) $Mef2c^{+/+}$ and (B) $Mef2c^{-/-}$ embryos were collected at 9.5 days post-coitum, fixed in 4% paraformaldeyde overnight, and stained with anti-PECAM antibody as previously described (De Val *et al.*, *Dev Biol.* 275, 2004). Consistent with previous reports (Lin *et al.*, *Development* 125, 1998), PECAM staining was detected in the Mef2c null embryo but was less extensive than in the wild-type control, indicating that vascular development was defective, but not abolished, in the absence of MEF2C. Arrows mark PECAM expression in intersomitic vessels. hrt, heart.



Figure S2. DNase I footprinting analysis identified regions of *Mef2c* F10-44 protected by binding activities present in extracts of the MS-1 endothelial cell line but not in extracts from the C2C12 myoblast cell line. The two protected regions correspond to the FOX:ETS motif and ETS-B site within *Mef2c* F10-44. Arrows indicate regions of protection, which can be seen as the loss of cleaved bands in the presence of MS-1 cell extract compared to BSA or C2C12 cell extracts. DNAse I footprinting was performed as described by Kucharczuk and Goldhamer, *Methods in Cell Biology* 52, 1997. The F10-44 probe was labeled by filling in recessed 3' ends with Klenow fragment and radiolabeled dCTP. Probes were purified using micro bio-spin P-30 Tris chromatography columns (BioRad). Cell extracts were prepared as described by Francis *et al.*, *Mol Endocrinol.* 20, 2006.



Figure S3. Ets and Forkhead proteins used in these studies were efficiently synthesized *in vitro* and bound efficiently to canonical, control sequences. (A-B) Ets (A) and Forkhead (B) proteins used in these studies were efficiently synthesized in coupled transcription-translation reactions *in vitro*. Proteins were labeled using [35 S]-Methionine.

(C) EMSA demonstrating that all four Ets proteins used in the EMSA shown in Figs. 2B and 2F bound to their canonical binding sites (lanes 2, 4, 6, and 8). In each case, the protein was made alongside the radiolabeled protein seen in (A) and was the same batch of protein used for the EMSAs shown in Fig. 2. The canonical sites used in these assays are shown in Supplemental Material, Table S4.

(D) EMSA demonstrating that the six Forkhead proteins used in the EMSA shown in Figs. 2C and 2F bound to their consensus sites (lanes 2, 4, 6, 8, 10, and 12). In each case, the protein was made alongside the radiolabeled protein shown in (B) and was the same batch of protein used for the EMSAs shown in Fig. 2. The canonical sites used in these assays are shown in Supplemental Material, Table S4.

MOUSE HUMAN OPPOSUM CHICKEN	eq:caaagcatgtttactagttcaacatggtcaaaatatacctaagttaaaggtcaaagaataaaacatgtttactagttcaacaaagccaaa-tgtacctaagggaaaggtcaaaggataaaacatgtttactagctcaaccaagtcaaaatgtacttaaggtaaaggtcaaggaataaaaacatgtttactagttctgtgctgctaaaatgttcataaggtaaaggtcaaagaataaaaacatgtttactagttcaagaataaaatgttcataaggtaaaggtcaaagaataaaaacatgtttactagttcaaagaataaaatgttcataaggtaaaggtcaaagaataaaaacatgtttactagttcaagaataaaatgttcataaggtaaaggtcaaagaataaaaaaaa
	*** ********** ** * * *** * * ***** ****
MOUSE HUMAN OPPOSUM CHICKEN	CCTACATTCCCTGCTGAGCTAACTCAGGAAGCACATTTGTCTACGCTTTCCTGTCAT ACTTCATTCCCTGCTGAGCAAATGCTCAGGAAGCACATTTGTCTACATTTTCCTGTCAT GCTTCATTCCCTGCTGAGCAAATGGTCAGGAAGCACATTTGTCTGCA-TTTCCTGTCAT ATTTCTTTCCCTGCTGAGCAAATGGTCAGGAAGCACATTTGTCTGCA-TTTCCTGTCAT * * ********** ** *******************
MOUSE HUMAN OPPOSUM CHICKEN	AACAGGAAGAGAGTAACTTCTTCCTTCCCACAGTGGCTTCAGTTTTAGCTCCCAACTCC AACAGGAAGAGTGTAACTTCTTCCTTTCCACAATAGCCTAGGTTTTACCTCCTAACTCC AACAGGAAGAATGTAACTTCTTCCTTTCCACAATGGCTTAAGTTCTACCTCCCTAACTAC AACAGGAAGAGTGTAACTTCTTCCTCTCCACAATGGCTTCAGTTCTACCTCCCACCTCC **********************
MOUSE HUMAN OPPOSUM CHICKEN	AATATTTTCTCCCTCAGGGCCTTCCAAATCAATCCTTGCAAGACAGAA AATATTTTCTCCCCCAGGGCCTTCCAAATCAATCCTTGCAAGACAGA- AGCTTTTTTTTTTTTTTCCCTCCCTCAGGGCCTTCCAAATCAATC

Figure S4. Extended conservation of the region surrounding the *Mef2c* F10-44 enhancer. ClustalW analysis (Thompson *et al.*, *Nucleic Acids Res.* 22, 1994) was used to compare the sequence of the region surrounding *Mef2c* F10-44 enhancer (red) from mouse, human, opossum, and chicken. Asterisks denote nucleotides that have been perfectly conserved among all four species. No significant conservation within F10E was detected beyond the region shown.

GENE NAME	NO. OF HITS	FOX:ETS MOTIF	LOCATION	ANOTHER GENE WITHIN
				10KB OF MOTIF
ANGPT1	0			
ANGPT2	0			
CALCRL	1	TGATGTAACAGGAAGCT	CHR2:188,138,544- 188,138,560	N
CD34	1	TCCCCTAACAGGAAAGT	CHR1:204,452,173- 204,452,189	N
CDH5	1	AACAATAACAGGAAACC	CHR16:64,957,955- 64,957,971	Ν
CTGF	0			
CTNNB1	0			
CYR61	0			
DSCR1	0			
EDG1	0			
EDG3	0			
EDN1	0			
EFFMD1	0			
	0			
EFNAL	0			
EFINDZ	1		CUD0.127 COC 077	λT
ENG	1	CAAGAAAACAGGAAGIG	127,686,993	IN
EPHB4	0			
ESM1	2	AGAGAAAACAGGAATTA	CHR5:54,302,791-	Ν
		AACAGAAACAGGAAATA	54,302,807	Ν
			CHR5:54,302,814-	
			54,302,830	
F2R	0			
F2RL1	0			
F2RL3	0			
FLT1	0			
FOXC1	1	TGGCACAACAGGAAAGC	CHR6:1,564,936-1,564,952	Y
FOXC2	0			
GATA2	0			
GJA1	1	CAGAACAACAGGAAAGG	CHR6:121,801,453- 121,801,469	N
GJA7	0			
ICAM1	0			
TCAM2	0			
TGFBP1	0			
IGFBP2	0			
IGEBP3	0			
IGFBP4	1	AGGGAAAACAGGAAGGA	CHR17:35,855,300- 35,855,316	N
TGFBP5	0		,000,020	1
TGFBP6	0			1
TTGAS	0		1	
TTGB3	Ő			1
TIGD3	3	λλαλλαλαααλατα	CHP1.55 814 306-	N
		TATATATATATATATA	55 814 322	N
		CACCAAACACCAGCAACTC	CHP4.55 828 453-	N
		CITOULIUCUCUCUC	55 828 469	TN
			CHR4.55 828 525-	
			55 828 541	
KI.EO	0		JJ,020,JTL	
KI.FA	0			
	1	ͲλλλͲλλΟλΟΟΛλλΟΟ	CUDE:112 642 014	N
THINK4	1	IAAAAIAACAGGAAACC	112,643,030	N

LMO2	0			
MCAM	0			
MEF2C	1	GGAGGAAACAGGAAAGA	CHR5:88,155,425-	N
			88,155,441	
MFNG	0			
MMRN1	1	TACAGAAACAGGAAACC	CHR4:91,173,120-	N
			91,173,136	
NFATC3	0			
NFATC4	0			
NOS3	0			
NOTCH4	1	AGAATAAACAGGAAAGG	CHR6:32,299,043-	N
			32,299,059	
NR4A2	0			
NRP1	1	TCTGTAAACAGGAAAGA	CHR10:33,631,344-	N
			33,631,360	
PDGFRB	1	AAGCACAACAGGAAATG	CHR5:149,497,296-	N
			149,497,312	
PECAM1	0			
PODXL	0			
PPP1R16B	2	GGACAAAACAGGAAGCT	CHR20:36,874,399-	N
		GAAGCAAACAGGAAGCA	36,874,415	N
			CHR20:36,937,666-	
DDOOD	0		36,937,682	
PROCR	0			
PIN	0			
RHOJ DODO4	0			
ROBO4	0			
SELE CEDDINE1	0			
CDADCI 1	0			
SPARCLI MAI 1	1		QUD1 47 200 774	NT
TALL	1	CACAAIAACAGGAIGIG	CHRI:47,389,774-	IN
TUDC1	0		47,389,790	
	0			
	0			
	0			
	0			
VWF	U			

Table S1A: Endothelial gene set used in computational scan.

GENE NAME	NO.	FOX:ETS MOTIF	LOCATION	ANOTHER
	OF			GENE
	HITS			WITHIN
				10KB OF
				MOTIF
AATF	0			
ABCG2	0			
ACTB	0			
ACTN4	0			
ADAR	0			
AFG3L2	0			
AGPAT1	0			
AHSA1	0			
AKR1A1	0			
ALDOA	0			
ALDOC	0			
ANAPC5	0			
ANP32B	0			
ANXA2	0			
ANXA6	0			
AP2M1	0			
APLP2	0			
APOBEC3C	0			
ARF1	0			
ARF4	0			
ARF5	0			
ARHGAP1	0			
ARHGDIA	0			
ARHGEF18	0			
ARL2	0			
ARMET	0			
ARPC2	0			
ARPC3	0			
ARPC4	0			
ATP5A1	0			
ATP5G1	0			
ATP5G3	0			
ATP5H	0			
ATP5I	0			
ATP5J2	0			
ATP50	0			
BAT1	0			
BLOC1S1	0			
BRMS1	0			
BTBD2	0			
BTF3	0			
BUD31	0			
C14ORF2	0			
C210RF33	0			
C9ORF16	0			
CALM1	0			
CALM2	0			
CANX	0			
CAPNS1	0			
CAPZB	0			
CCBP2	0			
CCT3	0			
CCT7	0			
CDC2L2	0			
CENPB	0			

CFL1	0			
CGB7	0			
CHD4	0			
	0			
CHIII	0			
CIZI	0			
CKAPI	0			
CLSTN1	0			
CLTA	0			
CNTN1	0			
COBRA1	0			
COMMD4	0			
COPSE	0			
COVATI	0			
CON411	0			
COXSA	0			
COX5B	0			
COX6A1	0			
COX7A2L	0			
COX7C	0			
CPNE1	0			
CPNE6	0			
CREB3	0			1
CGK	1	CCACAAAACACCAACCC	CHP15,72 856 902-72 856 019	N
CONVIE		GCAGAAAACAGGAAGCC	CHR15:72,858,902-72,858,918	IN
CSNKIE	0			
CSNK2B	0			
CSTB	0			
CTBP1	0			
CXYORF3	0			
CYC1	0			
DAD1	0			
	0			
	0			
	0			
DDUST	0		QUEE 140 010 160 140 010 104	37
DIAPHI		ACCACAAACAGGAAATG	CHR5:140,918,168-140,918,184	N
DKK4	0			
DNPEP	0			
DRAP1	0			
DULLARD	0			
DUOXA1	0			
DYNLL1	0			
ETF3S2	0			
ETE3C/	0			
EIFSGE	0			
ELF355	0			
EIF358	0			
EIF4A2	0			
EIF4G2	0			
ENTPD6	0			
ERP29	0			
EXTL3	0			
FAU	0			
FBX07	0			
FCER2	0			1
	0			
	0			
	0			
FTHI	U			
GABARAP	0			
GABARAPL2	0			
GANAB	0			
GAS1	0			
GDT1	1			t
	0			
GDT2	0			
GDI2	0			

GM2A	0			
GNAI2	1	CAGAAAAACAGGAAGGG	CHR3:50,267,523-50,267,539	Ν
GNAS	0			
GNB2	0			
GPAA1	0			
GPT	0			
GRIK5	0			
CPMA	0			
CCK2A	0			
GBRSA CUV1	0			
GUKI	0			
	0			
H3F3A	0			
H6PD	0			
HADHA	0			
HADHB	0			
HAX1	0			
HIST1H2BC	0			
HLA-C	0			
HNRPD	0			
HNRPH1	0			
HPCAL1	0			
HSBP1	0			
HSP90AB1	0			
HYOU1	0			
IDH3B	0			
IER2	0			
 TFTTM1	0			
TIK	0			
TMPDH2	0			
	0			
KDFLP1	0			
KDELKI VIE1C	0			
KIFIC KIFC2	0			
KIFC3	0			
LASPI	0			
LDHA	0			
LDHB	0			
LYPLA2	0			
MAP4	0			
MAPK8IP1	0			
MC2R	0			
MCM3AP	0			
MDH1	0			
MEA1	0			
MFN2	0			
MLF2				
MRLC2	0			
MRPL23	0			
MRPL9	0			
MRPS12	0			
MSN	0			
MTX1	0			
MVK	0			
MVT.6	0			
	0			
NDUEAT	0			
NDUFAZ	0			
NDUFA/	0			
NDUFB7	U			
NDUFCI	U			
NDUFS5	0			
NONO	0			
NUDT3	0			

NXF1	0			
ODC1	0			
	0			
PADPU1	0			
PABPNI	0			
PAK4	0			
PAX8	0			
PCGF2	0			
PDAP1	0			
PFDN1	1	CTGCACAACAGGAAAAG	CHR5:139,653,654-139,653,670	Ν
PFDN5	0			
PCD	0			
DCK1	0			
PGKI	0			
PHFI	0			
PHGDH	1			
PITPNM1	0			
PKM2	0			
PLSCR3	0			
POLR2F	0			
PPP1R11	0			
PPP2CB	0			
PPP2R1A	0			
	0			
DDVAC1	0			
PRRAGI	0			
PRPF8	0			
PRPH	0			
PSMB1	0			
PSMB2	0			
PSMB4	0			
PSMB7	0			
PSMD11	0			
PSMD8	0			
PTBP1	0			
PTDSS1	0			
PTTG1TP	0			
DAR1A	0			
DADOA	0			
RADOA DADAGI	0			
RABACI	0			
RAD23A	0			
RAD9A	0			
RAN	0			
RBM8A	0			
RBPMS	0			
RERE	1	GTTTATAACAGGAAGTG	CHR1:8,817,287-8,817,303	N
RNPS1	0			
RPA2	0			
RPL10	0			
RPI,10A	0			
RDT.11	0			
	0			
	0			
RPLIJA	0			
КРЦ14	0			
RPL15	0			
RPL17	0			
RPL18	0			
RPL19	0			
RPL27	0			
RPL29	0			
RPL3	0			
RPL32	0			
RPL34	0			
RPL35	0			
		1		1

RPL36AL	0		
RPI 37	0		
RPI 38	0		
RPL5	0		
RPI.8	0		
RPI.P1	0		
RDI.D2	0		
PDN1	0		
DDC10	0		
DDC11	0		
DDC12	0		
DDC14	0		
RPS14 DDC1E	0		
RPS15	0		
RPS10	0		
RPS18	0		
RPS19	0		
RPS2	0		
RPSZ4	0		
KPSZ5	0		
KP52/A	0		
KPS5	0		
RPS6KB2	0		
RPS9	0		
RRBPI	0		
RUVBL2	0		
SAFB	0		
SAP18	0		
SCAMP3	0		
SDHA	0		
SEC61B	0		
SEC61G	0		
SFRS9	0		
SGSH	0		
SIAHBP1	0		
SLC25A1	0		
SLC25A11	0		
SLC25A3	0		
SLC6A7	0		
SLC6A8	0		
SLC9A3R2	0		
SNRP70	0		
SNRPA	0		
SNRPB	0		
SNRPG	0		
SNX3	0		
SPAG7	0		
SRM	0		
SRRM1	0		
SSR2	0		
SSTR5	0		
STARD7	0		
STK19	0		
STK24	0		
SUMO2	0		
SUMO3	0		
SYNGR2	0		
TADA3L	0		
TAGLN	0		
TALDO1	0		
TAPBP	0		
TCEB2	0		

TCOF1	0		
TEGT	0		
TERF2IP	0		
TETRAN	0		
TEX261	0		
TKT	0		
TLN1	0		
TMED2	0		
TMEM4	0		
TMSB10	0		
TPMT	0		
TRAP1	0		
TSFM	0		
TSTA3	0		
TTC1	0		
TUBB4	0		
TUBGCP2	0		
TUT1	0		
UBE1	0		
UBE2D2	0		
UBE2I	0		
UBE2M	0		
UQCR	0		
UQCRC1	0		
UQCRFS1	0		
UQCRH	0		
USP11	0		
VIL2	0		
WDR1	0		
YARS	0		
YWHAH	0		
YWHAQ	0		
YWHAZ	0		
ZFPL1	0		
ZNF384	0		
ZNF91	0		

Table S1B: Housekeeping gene set used in computational scan.

GENE NAME	NO.	FOX:ETS MOTIF	LOCATION	ANOTHER
	OF			GENE
	HITS			WITHIN
				10KB OF
				MOTIF
ALDOA	0			
ΑΤΡ2Α1	0			
	0			
	0			
CD 2	0			
	0			
CACNAIS	0			
CACNGI	0			
CASQI	0			
CFL2	0			
	0			
CMIAS	0			
COX6A2	0			
CPTIB	0			
DES	0			
DUSP13	0			
DYSF	0			
DYSFIP1	0			
EEF1A2	0			
ENO3	0			
FLNC	0			
GAA	0			
GANAB	0			
HFE2	0			
KCNA7	0			
LMCD1	0			
MUSTN1	0			
MYBPC1	0			
MYBPC2	0			
МҮВРН	0			
MYF5	0			
MYF6	0			
МУН1	0			
MYH2	0			
МУН4	0			
MVT.1	0			
MVI.6R	0			
MATRO	0			
MILKZ	0			
MYO19P	0			
MYOC	0			
MIOG	0			
MYOM2	0			
MYOT	0			
MYOZI	0			
MYOZ2	0			
NEB	0			
PDK4	0			
PF'KM	0			
PGAM2	0			
PHKA1	0			
PRKAA2	0			
PRRX1	0			
PVALB	0			
PYGM	0			
PYGM	0			
RYR1	0			

SGCA	0		
SGCG	0		
SIX1	0		
SMPX	0		
SMYD1	0		
SRL	0		
TCAP	0		
TMOD4	0		
TNNC1	0		
TNNC2	0		
TNNI1	0		
TNNI2	0		
TNNT3	0		
TPM2	0		
TPM3	0		
TRDN	0		
TTN	0		
UGP2	0		
UNC45B	0		
ZNF185	0		

Table S1C: Skeletal muscle gene set used in computational scan.

Gene name	FOX:ETS motif (human sequence)	Location (human 2004 assembly)	Bind in EMSA	Conservation	Endothelial specific enhancer	Endothelial/ Express/Tg
FLT4	TAGGAAAACAGGAAGTG	chr5:179983112- 179983128	yes	Human: Xenopus	Yes	4/4/7
FOXP1	AGTCCAAACAGGAAAGG	chr3:71576377- 71576393	yes	Human: Fugu	Yes	4/3/6
NRP1	TCTGTAAACAGGAAAGA	chr10:33631344- 33631360	yes	Human: chicken	Yes	7/7/7
ECE1	TAGCTAAACAGGAAGGG	chr1:21351860- 21351876	yes	Human: opposum	Yes	5/5/8
PDGFRB	AAGCACAACAGGAAATG	chr5:149497296- 149497312	yes	Human: opposum	Yes	4/4/7
FGFR2	GAGAAAAACAGGATATT	chr10:123346296- 123346312	Yes	Human: chicken	No	0/1/6
NR4A3	TGATAAAACAGGAAAAC	chr9:99656354- 99656364	Yes	Human: chicken	No	0/5/8
EFNB1	CAGCCAAACAGGAAGAT	chr23:67854018- 67854034	Yes	Human: chicken	No	0/3/5
WNT2B	TTCTGAAACAGGAAAAC	chr1:112765333- 112765349	Yes	Human: chicken	ND	
STAT5B	AATACAAACAGGAAGCA	chr17:37678267- 37678283	Yes	Human: Xenopus	ND	
ESM1	AACAGAAACAGGAAATA	chr5:54302814- 54302830	No	Human: chicken	ND	
FOXO1A	GTGAAAAACAGGAATTT	chr13:40036590- 40036606	No	Human: chicken	ND	
RAC1	CAGAGAAACAGGAAATG	chr7:6187392- 6187408	No	Human: chicken	ND	

Table S2. Putative enhancers identified in genome-wide scan for FOX:ETS motifs.

Primer name	Primer sequence
mef2c-F10 (+)	catctccttttcccqqqqtttcc
mef2c-F10(-)	ccttctcccqqqcccatctctqt
mef2c-F10 •44 (+)	gttactgttagctcagcagggaat
mef2c-F10 •44 (-)	gctaacagtaacttcttccttcccac
mef2c-F10 44bp (+)	tcgagcaggaagcacatttgtctacgctttcctgtcataac
	aqqaaqaqa
mef2c-F10 44bp (-)	agcttctcttcctgttatgacaggaaagcgtagacaaatgt
-	gcttcctgc
mef2c-F10 mutFOX:ETS (+)	tgtcata t c ta gaagagagtaact
mef2c-F10 mutFOX:ETS (-)	agttactctcttc ta gatatgaca
VE-CADHERIN 377bp (+)	aggagggtt <u>actaqt</u> gatgctgca
VE-CADHERIN 377bp (-)	agggctgagca <u>ctaqt</u> ggagctctgtgg
VE-CADHERIN 3.5kb (+)	agtgccctggga <u>actaqt</u> aagagggagt
VE-CADHERIN 3.5kb (-)	ttcc <u>actaqt</u> ctgcctgtccgtccagg
VE-CADHERIN 3.5kb mutFOX:ETS	aagg c ac c ata tg agg c aaccatcccaggg
(+)	
VE-CADHERIN 3.5kb mutFOX:ETS (-)	ggttgcct ca tat g gt g cctttgtgagggc
Flk1 enhancer (+)	acaagaaatgtcagtgggcc
Flk1 enhancer (-)	gggattgactttgccccagt
NOTCH4 enhancer (+)	cacactcccgggcaggtcccttgtc
NOTCH4 enhancer (-)	ggctcaatgctcggcctttccgg
Tie2 promoter (+)	tgtcagggtacccaaatgcaccccagag
Tie2 promoter (-)	tccacactcgagcatgagtccctgggaa
Mef2c ChIP PCR (+)	tattggagttgggagctaaa
Mef2c ChIP PCR (-)	ctacattccctgctgagcta
Ve-cadherin ChIP PCR (+)	caccgcagggcctgcctat
Ve-cadherin ChIP PCR (-)	tgtcagccgaccgtctttgga
Flk1 ChIP PCR (+)	aagaccttgaagttggcaac
Flk1 ChIP PCR (-)	gggattgactttgccccagt
Tal1 ChIP PCR (+)	ccagctcctacttaagctct
Tall ChIP PCR (-)	ctgctatcggcacagcagt
Notch4 ChIP PCR (+)	caggccttccattcatagct
Notch4 ChIP PCR (-)	ttaggtgtctcagccattca
Tie2 ChIP PCR (+)	caagccctgctgataccaagt
Tie2 ChIP PCR (-)	caaggagaaacaccacagaa
FLT4 putative enhancer (+)	acagga <u>cccqqq</u> atagtgaggcaga
FLT4 putative enhancer (-)	aggaga <u>cccqqq</u> ccattactgccat
PDGFRS putative enhancer (+)	agtcaa <u>aagctt</u> ccacgtcccaagcct
PDGFRß putative enhancer (-)	gagagc <u>aaqctt</u> caccccattcagt
ECE1 putative enhancer (+)	cataat <u>cccqqq</u> gcaaaaacacgcga
ECE1 putative enhancer (-)	tgactga <u>cccqqq</u> ccagacatcacc
NRP1 putative enhancer (+)	tcagga <u>cccqqq</u> tcatgggcatgcat
NRPI putative enhancer (-)	agattt <u>cccqqq</u> ttcatactggct
FOXPI putative enhancer (+)	ctctcc <u>aaqctt</u> ctcaacagtcat
FOXPI putative enhancer (-)	ctccagaaqcttttgctattgctgtt
FGFR2 putative enhancer (+)	
FGFR2 putative enhancer (-)	aggaccaaqcttctgcgtttggagt
NR4A3 putative enhancer (+)	
NR4A3 putative enhancer (-)	gatagt <u>cccqqq</u> ctcactttatgatt
EFNBI putative enhancer (+)	
EFINEL putative enhancer (-)	yayayı <u>cccqqq</u> cııgaaaıccca
FOXCIA MOIPHOIIHO	
	gaadtattaattaaaaaa
$\frac{r_{\rm LKL}}{r_{\rm LKL}} \frac{q_{\rm LKK}}{q_{\rm LKL}} \left(+ \right)$	gyayuuduugguuudaagaa
PIRI YPCK (-)	
Pecam qPCK (+)	algagigtgacgtgttctgtg

Pecam qPCR (-)	gacagccatgcaatgtctatg

Table S3: Oligonucleotide primers for cloning, mutagenesis, morpholino knockdown, qPCR, and ChIP.

Oligo name	Oligo sequence
Mef2c-F10-44 FOX-NC (+)	ggaagttactctcttcctgttatgacaggaaagcgtagaca
Mef2c-F10-44 mut FOX-NC (+)	ggaagttactctcttc ta g a tatgacaggaaagcgtagaca
Mef2c-F10 FOX:ETS (+)	aagttactcttcctgttatgacagg
<i>Mef2c</i> -F10-44 ETS-A (+)	ggagttactctcttcctgttatgaca
Mef2c-F10-44 mutETSA (+)	ggagttactctcttc ta g a tatgaca
Flk1 FOX:ETS (+)	ggctgcccattcttcctgttatgacagagcttgtgaa
Flk1 mutFOX:ETS (+)	ggctgcccattcttcc acggcc gacagagcttgtgaa
Tall FOX:ETS (+)	ggcgaacggatcacatcctgttattgtgtggaaagaaaga
Tal1 mutFOX:ETS (+)	ggcgaacggatcacatcctg agc t c gtgtggaaagaaagaa
CDH5 FOX:ETS (+)	ggcctcgggatggtttcctgttattgttcctttgtgagctg
CDH5 mutFOX:ETS (+)	ggcctcgggatggtttcctg agctc gttcctttgtgagctg
NOTCH4 FOX:ETS (+)	ggccctaccccctttcctgtttattctctggcctc
NOTCH4 mutFOX:ETS (+)	ggccctaccccctttcc acca tattctctggcctc
Tek FOX:ETS (+)	ggtgcaaaggaaacaggaaaaaggaactt
Tek mutFOX:ETS (+)	ggtgcaaaggaa tcta gaaaaaggaactt
FoxC1/2 control site (+)	ggggaggagcagcctgtttgttttgccagatctgtgc
FoxF1/FoxA2 control site (+)	ggcttgcacgtaattgtttstttacgagcgt
FoxH1 control site (+)	gggattagaagatgtggattgcgtccgg
FoxO1 control site (+)	gggacgttttaggttgtttattcct
Ets1/ER71 control site (+)	ggaaccaagcttgagtaccggaagagtacaccg
Erg control site (+)	gggagagtgcaccggaagtcagttaa
Elf1 control site (+)	taaacccggaagtgtagtacatctggatcg

Table S4: Sense strand sequence of oligonucleotide probes used in EMSA. For the mutant FOX:ETS oligonucleotides for *Mef2c*, *Flk1*, *Tal1*, *CDH5*, *NOTCH4*, and *Tek*, the mutations were confirmed experimentally to disrupt binding in EMSA by FoxC2, Etv2, and the Ets1 DNA binding domain.